FDA Approves Canakinumab for Adult-Onset Still’s Disease
Interleukin 17 Inhibitors Promising in Ankylosing Spondylitis Patients
Biologic Treatment Recommendations for Rheumatic Disease Patients Who Contract COVID-19
ABX464 in Phase 2a Trials for RA
Researchers Give Update on Janus Kinase (JAK) Inhibitors
Risankizumab & Apremilast Come to Market in Canada
Phase 3 Results for Olokizumab in RA Patients
Low-Dose Methotrexate Can Cause Adverse Effects
Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis
- 1
- 2
- 3
- …
- 19
- Next Page »